nodes	percent_of_prediction	percent_of_DWPC	metapath
Finasteride—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.21	0.27	CbGbCtD
Finasteride—CYP3A7—Sorafenib—thyroid cancer	0.21	0.27	CbGbCtD
Finasteride—CYP3A5—Sorafenib—thyroid cancer	0.158	0.202	CbGbCtD
Finasteride—CYP3A4—Vandetanib—thyroid cancer	0.102	0.131	CbGbCtD
Finasteride—CYP3A4—Sorafenib—thyroid cancer	0.0615	0.079	CbGbCtD
Finasteride—CYP3A4—Doxorubicin—thyroid cancer	0.0373	0.0479	CbGbCtD
Finasteride—Musculoskeletal disorder—Vandetanib—thyroid cancer	0.0194	0.137	CcSEcCtD
Finasteride—AKR1D1—Synthesis of bile acids and bile salts via 27-hydroxycholesterol—RXRA—thyroid cancer	0.0114	0.143	CbGpPWpGaD
Finasteride—AKR1D1—Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol—RXRA—thyroid cancer	0.0078	0.0985	CbGpPWpGaD
Finasteride—AKR1D1—Synthesis of bile acids and bile salts—RXRA—thyroid cancer	0.0071	0.0896	CbGpPWpGaD
Finasteride—Neoplasm—Vandetanib—thyroid cancer	0.00627	0.0442	CcSEcCtD
Finasteride—AKR1D1—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.00564	0.0712	CbGpPWpGaD
Finasteride—Neoplasm malignant—Sorafenib—thyroid cancer	0.00547	0.0386	CcSEcCtD
Finasteride—AKR1D1—Metapathway biotransformation—CHST14—thyroid cancer	0.00547	0.069	CbGpPWpGaD
Finasteride—Influenza—Vandetanib—thyroid cancer	0.00435	0.0307	CcSEcCtD
Finasteride—Neoplasm—Sorafenib—thyroid cancer	0.00423	0.0298	CcSEcCtD
Finasteride—Gynaecomastia—Sorafenib—thyroid cancer	0.00418	0.0295	CcSEcCtD
Finasteride—Bronchitis—Vandetanib—thyroid cancer	0.00418	0.0295	CcSEcCtD
Finasteride—Prostatic disorder—Epirubicin—thyroid cancer	0.00406	0.0287	CcSEcCtD
Finasteride—Prostatic disorder—Doxorubicin—thyroid cancer	0.00376	0.0265	CcSEcCtD
Finasteride—Sinusitis—Vandetanib—thyroid cancer	0.00364	0.0257	CcSEcCtD
Finasteride—Breast disorder—Sorafenib—thyroid cancer	0.00307	0.0216	CcSEcCtD
Finasteride—Mental disorder—Vandetanib—thyroid cancer	0.00305	0.0215	CcSEcCtD
Finasteride—Erectile dysfunction—Sorafenib—thyroid cancer	0.0027	0.0191	CcSEcCtD
Finasteride—Infection—Vandetanib—thyroid cancer	0.00246	0.0173	CcSEcCtD
Finasteride—Dyspnoea—Vandetanib—thyroid cancer	0.0022	0.0155	CcSEcCtD
Finasteride—Immune system disorder—Sorafenib—thyroid cancer	0.00212	0.015	CcSEcCtD
Finasteride—Pain—Vandetanib—thyroid cancer	0.00211	0.0149	CcSEcCtD
Finasteride—Mental disorder—Sorafenib—thyroid cancer	0.00206	0.0145	CcSEcCtD
Finasteride—Neoplasm malignant—Epirubicin—thyroid cancer	0.00202	0.0143	CcSEcCtD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00192	0.0243	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00192	0.0243	CbGpPWpGaD
Finasteride—Neoplasm malignant—Doxorubicin—thyroid cancer	0.00187	0.0132	CcSEcCtD
Finasteride—Angioedema—Sorafenib—thyroid cancer	0.00187	0.0132	CcSEcCtD
Finasteride—Asthenia—Vandetanib—thyroid cancer	0.00177	0.0125	CcSEcCtD
Finasteride—Pruritus—Vandetanib—thyroid cancer	0.00175	0.0123	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00172	0.0217	CbGpPWpGaD
Finasteride—Infection—Sorafenib—thyroid cancer	0.00166	0.0117	CcSEcCtD
Finasteride—Dizziness—Vandetanib—thyroid cancer	0.00163	0.0115	CcSEcCtD
Finasteride—Neoplasm—Epirubicin—thyroid cancer	0.00156	0.011	CcSEcCtD
Finasteride—Rash—Vandetanib—thyroid cancer	0.00156	0.011	CcSEcCtD
Finasteride—Dermatitis—Vandetanib—thyroid cancer	0.00156	0.011	CcSEcCtD
Finasteride—Headache—Vandetanib—thyroid cancer	0.00155	0.0109	CcSEcCtD
Finasteride—Dyspnoea—Sorafenib—thyroid cancer	0.00149	0.0105	CcSEcCtD
Finasteride—Neoplasm—Doxorubicin—thyroid cancer	0.00145	0.0102	CcSEcCtD
Finasteride—Pain—Sorafenib—thyroid cancer	0.00143	0.0101	CcSEcCtD
Finasteride—SRD5A2—Metabolism—MINPP1—thyroid cancer	0.00133	0.0168	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—MINPP1—thyroid cancer	0.00133	0.0168	CbGpPWpGaD
Finasteride—Urticaria—Sorafenib—thyroid cancer	0.00132	0.00935	CcSEcCtD
Finasteride—Hypersensitivity—Sorafenib—thyroid cancer	0.00123	0.00867	CcSEcCtD
Finasteride—Asthenia—Sorafenib—thyroid cancer	0.0012	0.00844	CcSEcCtD
Finasteride—AKR1D1—Metabolism—MINPP1—thyroid cancer	0.00119	0.015	CbGpPWpGaD
Finasteride—Pruritus—Sorafenib—thyroid cancer	0.00118	0.00832	CcSEcCtD
Finasteride—CYP3A7—Metapathway biotransformation—CHST14—thyroid cancer	0.00116	0.0146	CbGpPWpGaD
Finasteride—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00115	0.00808	CcSEcCtD
Finasteride—Breast disorder—Epirubicin—thyroid cancer	0.00113	0.00799	CcSEcCtD
Finasteride—SRD5A2—Metabolism—NDUFA13—thyroid cancer	0.00113	0.0143	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—NDUFA13—thyroid cancer	0.00113	0.0143	CbGpPWpGaD
Finasteride—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00112	0.0141	CbGpPWpGaD
Finasteride—Dizziness—Sorafenib—thyroid cancer	0.0011	0.00778	CcSEcCtD
Finasteride—Influenza—Epirubicin—thyroid cancer	0.00108	0.00764	CcSEcCtD
Finasteride—SRD5A1—Metabolism—CHST14—thyroid cancer	0.00106	0.0134	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—CHST14—thyroid cancer	0.00106	0.0134	CbGpPWpGaD
Finasteride—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00106	0.00748	CcSEcCtD
Finasteride—Rash—Sorafenib—thyroid cancer	0.00105	0.00742	CcSEcCtD
Finasteride—Dermatitis—Sorafenib—thyroid cancer	0.00105	0.00741	CcSEcCtD
Finasteride—Breast disorder—Doxorubicin—thyroid cancer	0.00105	0.0074	CcSEcCtD
Finasteride—Headache—Sorafenib—thyroid cancer	0.00104	0.00737	CcSEcCtD
Finasteride—Bronchitis—Epirubicin—thyroid cancer	0.00104	0.00735	CcSEcCtD
Finasteride—AKR1D1—Metabolism—NDUFA13—thyroid cancer	0.00101	0.0127	CbGpPWpGaD
Finasteride—Influenza—Doxorubicin—thyroid cancer	0.001	0.00707	CcSEcCtD
Finasteride—Bronchitis—Doxorubicin—thyroid cancer	0.000964	0.0068	CcSEcCtD
Finasteride—AKR1D1—Metabolism—CHST14—thyroid cancer	0.000948	0.012	CbGpPWpGaD
Finasteride—CYP3A5—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000948	0.012	CbGpPWpGaD
Finasteride—Sinusitis—Epirubicin—thyroid cancer	0.000907	0.0064	CcSEcCtD
Finasteride—Rhinitis—Epirubicin—thyroid cancer	0.00087	0.00613	CcSEcCtD
Finasteride—Pharyngitis—Epirubicin—thyroid cancer	0.000861	0.00607	CcSEcCtD
Finasteride—SRD5A1—Metabolism—HPGD—thyroid cancer	0.000857	0.0108	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—HPGD—thyroid cancer	0.000857	0.0108	CbGpPWpGaD
Finasteride—Oedema peripheral—Epirubicin—thyroid cancer	0.000855	0.00603	CcSEcCtD
Finasteride—Sinusitis—Doxorubicin—thyroid cancer	0.000839	0.00592	CcSEcCtD
Finasteride—CYP3A5—Metapathway biotransformation—CHST14—thyroid cancer	0.000836	0.0106	CbGpPWpGaD
Finasteride—Rhinitis—Doxorubicin—thyroid cancer	0.000805	0.00568	CcSEcCtD
Finasteride—Pharyngitis—Doxorubicin—thyroid cancer	0.000797	0.00562	CcSEcCtD
Finasteride—CYP3A7—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000793	0.01	CbGpPWpGaD
Finasteride—Oedema peripheral—Doxorubicin—thyroid cancer	0.000791	0.00558	CcSEcCtD
Finasteride—Immune system disorder—Epirubicin—thyroid cancer	0.000784	0.00553	CcSEcCtD
Finasteride—AKR1D1—Metabolism—HPGD—thyroid cancer	0.000764	0.00965	CbGpPWpGaD
Finasteride—Mental disorder—Epirubicin—thyroid cancer	0.00076	0.00536	CcSEcCtD
Finasteride—Immune system disorder—Doxorubicin—thyroid cancer	0.000725	0.00511	CcSEcCtD
Finasteride—Mental disorder—Doxorubicin—thyroid cancer	0.000703	0.00496	CcSEcCtD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000695	0.00878	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000695	0.00878	CbGpPWpGaD
Finasteride—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000669	0.00844	CbGpPWpGaD
Finasteride—CYP3A7—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000643	0.00812	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.00062	0.00782	CbGpPWpGaD
Finasteride—Infection—Epirubicin—thyroid cancer	0.000612	0.00432	CcSEcCtD
Finasteride—Hypotension—Epirubicin—thyroid cancer	0.000576	0.00406	CcSEcCtD
Finasteride—CYP3A5—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000573	0.00724	CbGpPWpGaD
Finasteride—Infection—Doxorubicin—thyroid cancer	0.000567	0.004	CcSEcCtD
Finasteride—Dyspnoea—Epirubicin—thyroid cancer	0.000549	0.00388	CcSEcCtD
Finasteride—Somnolence—Epirubicin—thyroid cancer	0.000548	0.00386	CcSEcCtD
Finasteride—Hypotension—Doxorubicin—thyroid cancer	0.000533	0.00376	CcSEcCtD
Finasteride—Pain—Epirubicin—thyroid cancer	0.000527	0.00372	CcSEcCtD
Finasteride—Dyspnoea—Doxorubicin—thyroid cancer	0.000508	0.00359	CcSEcCtD
Finasteride—Somnolence—Doxorubicin—thyroid cancer	0.000507	0.00358	CcSEcCtD
Finasteride—SRD5A2—Metabolism—TPR—thyroid cancer	0.000492	0.00622	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—TPR—thyroid cancer	0.000492	0.00622	CbGpPWpGaD
Finasteride—Urticaria—Epirubicin—thyroid cancer	0.00049	0.00345	CcSEcCtD
Finasteride—Pain—Doxorubicin—thyroid cancer	0.000488	0.00344	CcSEcCtD
Finasteride—SRD5A2—Metabolism—PRKAR1A—thyroid cancer	0.000484	0.00612	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—PRKAR1A—thyroid cancer	0.000484	0.00612	CbGpPWpGaD
Finasteride—CYP3A5—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000465	0.00587	CbGpPWpGaD
Finasteride—Hypersensitivity—Epirubicin—thyroid cancer	0.000454	0.0032	CcSEcCtD
Finasteride—Urticaria—Doxorubicin—thyroid cancer	0.000453	0.0032	CcSEcCtD
Finasteride—Asthenia—Epirubicin—thyroid cancer	0.000442	0.00312	CcSEcCtD
Finasteride—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000441	0.00556	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000439	0.00554	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000439	0.00554	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—TPR—thyroid cancer	0.000439	0.00554	CbGpPWpGaD
Finasteride—Pruritus—Epirubicin—thyroid cancer	0.000436	0.00308	CcSEcCtD
Finasteride—AKR1D1—Metabolism—PRKAR1A—thyroid cancer	0.000432	0.00545	CbGpPWpGaD
Finasteride—Hypersensitivity—Doxorubicin—thyroid cancer	0.00042	0.00296	CcSEcCtD
Finasteride—Asthenia—Doxorubicin—thyroid cancer	0.000409	0.00289	CcSEcCtD
Finasteride—Dizziness—Epirubicin—thyroid cancer	0.000408	0.00287	CcSEcCtD
Finasteride—Pruritus—Doxorubicin—thyroid cancer	0.000403	0.00285	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000391	0.00494	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000389	0.00491	CbGpPWpGaD
Finasteride—Rash—Epirubicin—thyroid cancer	0.000389	0.00274	CcSEcCtD
Finasteride—Dermatitis—Epirubicin—thyroid cancer	0.000388	0.00274	CcSEcCtD
Finasteride—Headache—Epirubicin—thyroid cancer	0.000386	0.00272	CcSEcCtD
Finasteride—Dizziness—Doxorubicin—thyroid cancer	0.000377	0.00266	CcSEcCtD
Finasteride—SRD5A1—Metabolism—SLC5A5—thyroid cancer	0.000369	0.00465	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—SLC5A5—thyroid cancer	0.000369	0.00465	CbGpPWpGaD
Finasteride—Rash—Doxorubicin—thyroid cancer	0.00036	0.00254	CcSEcCtD
Finasteride—Dermatitis—Doxorubicin—thyroid cancer	0.000359	0.00253	CcSEcCtD
Finasteride—Headache—Doxorubicin—thyroid cancer	0.000357	0.00252	CcSEcCtD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000345	0.00436	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000345	0.00436	CbGpPWpGaD
Finasteride—CYP3A7—Biological oxidations—RXRA—thyroid cancer	0.000341	0.00431	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—SLC5A5—thyroid cancer	0.000328	0.00415	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—RXRA—thyroid cancer	0.00031	0.00391	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—RXRA—thyroid cancer	0.00031	0.00391	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000308	0.00389	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000301	0.0038	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000301	0.0038	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—RXRA—thyroid cancer	0.000276	0.00348	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000268	0.00339	CbGpPWpGaD
Finasteride—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000266	0.00336	CbGpPWpGaD
Finasteride—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000265	0.00335	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—MINPP1—thyroid cancer	0.000251	0.00317	CbGpPWpGaD
Finasteride—CYP3A5—Biological oxidations—RXRA—thyroid cancer	0.000247	0.00312	CbGpPWpGaD
Finasteride—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000216	0.00273	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—NDUFA13—thyroid cancer	0.000213	0.00269	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—CHST14—thyroid cancer	0.000201	0.00253	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—PPARG—thyroid cancer	0.000195	0.00247	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—PPARG—thyroid cancer	0.000195	0.00247	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—MINPP1—thyroid cancer	0.000181	0.00229	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—PPARG—thyroid cancer	0.000174	0.0022	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—HPGD—thyroid cancer	0.000162	0.00204	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—NDUFA13—thyroid cancer	0.000154	0.00195	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—PTGS2—thyroid cancer	0.000154	0.00194	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—PTGS2—thyroid cancer	0.000154	0.00194	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—CHST14—thyroid cancer	0.000145	0.00183	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—PTGS2—thyroid cancer	0.000137	0.00173	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—PTEN—thyroid cancer	0.000134	0.00169	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—PTEN—thyroid cancer	0.000134	0.00169	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—PTEN—thyroid cancer	0.00012	0.00151	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—HPGD—thyroid cancer	0.000117	0.00148	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000115	0.00145	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—TPR—thyroid cancer	9.28e-05	0.00117	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	9.13e-05	0.00115	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—MINPP1—thyroid cancer	8.43e-05	0.00106	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—AKT1—thyroid cancer	7.73e-05	0.000976	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—AKT1—thyroid cancer	7.73e-05	0.000976	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—NDUFA13—thyroid cancer	7.17e-05	0.000905	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—SLC5A5—thyroid cancer	6.95e-05	0.000878	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—AKT1—thyroid cancer	6.89e-05	0.00087	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—CHST14—thyroid cancer	6.74e-05	0.000851	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—TPR—thyroid cancer	6.71e-05	0.000847	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	6.6e-05	0.000834	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—RXRA—thyroid cancer	5.84e-05	0.000737	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—HPGD—thyroid cancer	5.43e-05	0.000686	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—SLC5A5—thyroid cancer	5.02e-05	0.000634	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—RXRA—thyroid cancer	4.22e-05	0.000533	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—PPARG—thyroid cancer	3.69e-05	0.000466	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—TPR—thyroid cancer	3.12e-05	0.000394	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.07e-05	0.000388	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—PTGS2—thyroid cancer	2.9e-05	0.000366	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—PPARG—thyroid cancer	2.66e-05	0.000337	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—PTEN—thyroid cancer	2.53e-05	0.000319	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.34e-05	0.000295	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—PTGS2—thyroid cancer	2.1e-05	0.000265	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—RXRA—thyroid cancer	1.96e-05	0.000248	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—PTEN—thyroid cancer	1.83e-05	0.000231	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—AKT1—thyroid cancer	1.46e-05	0.000184	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—PPARG—thyroid cancer	1.24e-05	0.000156	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—AKT1—thyroid cancer	1.05e-05	0.000133	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—PTGS2—thyroid cancer	9.75e-06	0.000123	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—PTEN—thyroid cancer	8.5e-06	0.000107	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—AKT1—thyroid cancer	4.9e-06	6.19e-05	CbGpPWpGaD
